Search

Your search keyword '"Heidelberger V"' showing total 3 results
Start Over Author "Heidelberger V" Topic skin neoplasms
3 results on '"Heidelberger V"'

1. Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Author

Hazard M, Duval F, Dutriaux C, Beylot-Barry M, Pham-Ledard A, Quereux G, Amini-Adle M, Heidelberger V, Aubin F, Saint-Jean M, Nardin C, Abed S, Leccia MT, Mansard S, Prey S, Khammari A, Dréno B, and Gérard E

Subjects
Humans, Antineoplastic Combined Chemotherapy Protocols, Melanoma drug therapy, Lung Neoplasms drug therapy, Skin Neoplasms drug therapy
Published
2024
Full Text
View/download PDF

2. Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.

Author

Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, and Dalac Rat S

Subjects
Humans, Antibodies, Monoclonal, Humanized therapeutic use, Duration of Therapy, Treatment Outcome, Time Factors, Carcinoma, Squamous Cell drug therapy, Skin Neoplasms drug therapy, Antineoplastic Agents therapeutic use
Published
2024
Full Text
View/download PDF

3. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma.

Author

Cǎlugǎreanu A, Rompteaux P, Bohelay G, Goldfarb L, Barrau V, Cucherousset N, Heidelberger V, Nault JC, Ziol M, Caux F, and Maubec E

Subjects
Adult, Antineoplastic Agents, Immunological adverse effects, Cholangitis etiology, Disease Progression, Duodenitis etiology, Female, Gastritis etiology, Humans, Melanoma diagnosis, Neoplasm Metastasis, Neoplasm Staging, Nivolumab adverse effects, Positron-Emission Tomography, Remission Induction, Skin Neoplasms diagnosis, Antineoplastic Agents, Immunological therapeutic use, Cholangitis diagnosis, Drug-Related Side Effects and Adverse Reactions diagnosis, Duodenitis diagnosis, Gastritis diagnosis, Immunotherapy adverse effects, Melanoma drug therapy, Nivolumab therapeutic use, Skin Neoplasms drug therapy
Abstract

Antiprogramed cell death-1 protein agents represent a therapeutic approach based on stimulating the host's immune response through blockade of immune checkpoints, inhibitory pathways that dampen the physiological peripheral T-cell immune response and are essential for maintaining self-tolerance. We describe the late onset of severe gastroduodenitis and cholangitis in a nivolumab-treated, metastatic melanoma patient in complete remission. Positron-emission tomography with computed tomography scans showed diffuse fluorodeoxyglucose (FDG) uptake in the stomach preceding upper digestive tract symptoms. Hence, positron-emission tomography with computed tomography might as well be a useful tool for early diagnosis of subclinical gastric toxicity as recently shown for colitis. Furthermore, physicians must be aware and remain vigilant to antiprogramed cell death-1 protein-related digestive toxicity that may appear very late during treatment.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results